Loading…

Browse All Grants

20,252 grants found

Filters
Reset

Showing 19,00119,020 of 20,252 grants

Completed NON-SBIR/STTR RPGS
Comprehensive analyses of HOXB13-regulated transcriptional programs critical for prostate cancer progression
NATIONAL CANCER INSTITUTE Northwestern University At Chicago United States 2021 – 2026

Summary Prostate cancer (PCa) is the most commonly diagnosed non-skin cancer in American men. Early-stage PCa can be effectively ablated with surgery and/or radiation treatments. H...

$4.85M
USD
Completed NON-SBIR/STTR RPGS
Circulating Genomic Determinants of Treatment Failure in Hodgkin Lymphoma
NATIONAL CANCER INSTITUTE Stanford University United States 2021 – 2026

PROJECT SUMMARY/ABSTRACT PIs: Ash Alizadeh, M.D./Ph.D. & Maximilian Diehn, M.D./Ph.D. Classical Hodgkin lymphoma (HL) is among the most curable human malignancies.However, stra...

$6.55M
USD
Completed NON-SBIR/STTR RPGS
Improving our understanding of breast cancer mortality disparities through recurrence: a multi-level approach among women in Georgia
NATIONAL CANCER INSTITUTE Emory University United States 2021 – 2026

PROJECT SUMMARY/ABSTRACT Significance.Although national and philanthropic efforts have sought to reduce and eliminate breast cancer (BC) mortality disparities over the past few dec...

$5.65M
USD
Completed NON-SBIR/STTR RPGS
Targeting Oncostatin M-Receptor to Suppress Metastasis and Therapy Failure
NATIONAL CANCER INSTITUTE Case Western Reserve University United States 2021 – 2026

ABSTRACT The metastatic spread of cancer cells and recurrence are intimately linked to therapy failure, which remains an important clinical challenge for patients with metastatic T...

$4.13M
USD
Completed NON-SBIR/STTR RPGS
Nanoparticle delivery of miRNA-based therapeutics to overcome clinical challenges in triple negative breast cancer
NATIONAL CANCER INSTITUTE Methodist Hospital Research Institute United States 2021 – 2026

Project Summary Triple-negative breast cancer (TNBC) has the highest patient death rate of all breast cancer subtypes.Several molecular targets have been identified for breast canc...

$4.13M
USD
Completed NON-SBIR/STTR RPGS
Targeting Oncostatin M-Receptor to Suppress Metastasis and Therapy Failure
NATIONAL CANCER INSTITUTE Case Western Reserve University United States 2021 – 2026

ABSTRACT The metastatic spread of cancer cells and recurrence are intimately linked to therapy failure, which remains an important clinical challenge for patients with metastatic T...

$3.92M
USD
Completed NON-SBIR/STTR RPGS
Circulating Genomic Determinants of Treatment Failure in Hodgkin Lymphoma
NATIONAL CANCER INSTITUTE Stanford University United States 2021 – 2026

PROJECT SUMMARY/ABSTRACT PIs: Ash Alizadeh, M.D./Ph.D. & Maximilian Diehn, M.D./Ph.D. Classical Hodgkin lymphoma (HL) is among the most curable human malignancies. However, str...

$6.21M
USD
Completed NON-SBIR/STTR RPGS
Nanoparticle delivery of miRNA-based therapeutics to overcome clinical challenges in triple negative breast cancer
NATIONAL CANCER INSTITUTE Methodist Hospital Research Institute United States 2021 – 2026

Project Summary Triple-negative breast cancer (TNBC) has the highest patient death rate of all breast cancer subtypes. Several molecular targets have been identified for breast can...

$3.78M
USD
Completed NON-SBIR/STTR RPGS
Improving our understanding of breast cancer mortality disparities through recurrence: a multi-level approach among women in Georgia
NATIONAL CANCER INSTITUTE Emory University United States 2021 – 2026

PROJECT SUMMARY/ABSTRACT Significance. Although national and philanthropic efforts have sought to reduce and eliminate breast cancer (BC) mortality disparities over the past few de...

$5.24M
USD
Completed NON-SBIR/STTR RPGS
Improving our understanding of breast cancer mortality disparities through recurrence: a multi-level approach among women in Georgia
NATIONAL CANCER INSTITUTE Emory University United States 2021 – 2026

PROJECT SUMMARY/ABSTRACT Significance. Although national and philanthropic efforts have sought to reduce and eliminate breast cancer (BC) mortality disparities over the past few de...

$1.27M
USD
Completed NON-SBIR/STTR RPGS
Targeting Oncostatin M-Receptor to Suppress Metastasis and Therapy Failure
NATIONAL CANCER INSTITUTE Case Western Reserve University United States 2021 – 2026

ABSTRACT The metastatic spread of cancer cells and recurrence are intimately linked to therapy failure, which remains an important clinical challenge for patients with metastatic T...

$4.05M
USD
Completed NON-SBIR/STTR RPGS
Improving our understanding of breast cancer mortality disparities through recurrence: a multi-level approach among women in Georgia
NATIONAL CANCER INSTITUTE Emory University United States 2021 – 2026

PROJECT SUMMARY/ABSTRACT Significance. Although national and philanthropic efforts have sought to reduce and eliminate breast cancer (BC) mortality disparities over the past few de...

$5.45M
USD
Completed NON-SBIR/STTR RPGS
Circulating Genomic Determinants of Treatment Failure in Hodgkin Lymphoma
NATIONAL CANCER INSTITUTE Stanford University United States 2021 – 2026

PROJECT SUMMARY/ABSTRACT PIs: Ash Alizadeh, M.D./Ph.D. & Maximilian Diehn, M.D./Ph.D. Classical Hodgkin lymphoma (HL) is among the most curable human malignancies. However, str...

$6.41M
USD
Completed NON-SBIR/STTR RPGS
Comprehensive analyses of HOXB13-regulated transcriptional programs critical for prostate cancer progression
NATIONAL CANCER INSTITUTE Northwestern University At Chicago United States 2021 – 2023

Summary Prostate cancer (PCa) is the most commonly diagnosed non-skin cancer in American men. Early-stage PCa can be effectively ablated with surgery and/or radiation treatments. H...

$4.78M
USD
Completed NON-SBIR/STTR RPGS
Nanoparticle delivery of miRNA-based therapeutics to overcome clinical challenges in triple negative breast cancer
NATIONAL CANCER INSTITUTE Methodist Hospital Research Institute United States 2021 – 2026

Project Summary Triple-negative breast cancer (TNBC) has the highest patient death rate of all breast cancer subtypes. Several molecular targets have been identified for breast can...

$3.9M
USD
Completed NON-SBIR/STTR RPGS
Improving our understanding of breast cancer mortality disparities through recurrence: a multi-level approach among women in Georgia
NATIONAL CANCER INSTITUTE Emory University United States 2021 – 2026

PROJECT SUMMARY/ABSTRACT Significance. Although national and philanthropic efforts have sought to reduce and eliminate breast cancer (BC) mortality disparities over the past few de...

$5.67M
USD
Completed NON-SBIR/STTR RPGS
Targeting Oncostatin M-Receptor to Suppress Metastasis and Therapy Failure
NATIONAL CANCER INSTITUTE Case Western Reserve University United States 2021 – 2026

ABSTRACT The metastatic spread of cancer cells and recurrence are intimately linked to therapy failure, which remains an important clinical challenge for patients with metastatic T...

$4.05M
USD
Completed NON-SBIR/STTR RPGS
Nanoparticle delivery of miRNA-based therapeutics to overcome clinical challenges in triple negative breast cancer
NATIONAL CANCER INSTITUTE Methodist Hospital Research Institute United States 2021 – 2026

Project Summary Triple-negative breast cancer (TNBC) has the highest patient death rate of all breast cancer subtypes. Several molecular targets have been identified for breast can...

$3.9M
USD
Completed NON-SBIR/STTR RPGS
Circulating Genomic Determinants of Treatment Failure in Hodgkin Lymphoma
NATIONAL CANCER INSTITUTE Stanford University United States 2021 – 2026

PROJECT SUMMARY/ABSTRACT PIs: Ash Alizadeh, M.D./Ph.D. & Maximilian Diehn, M.D./Ph.D. Classical Hodgkin lymphoma (HL) is among the most curable human malignancies. However, str...

$6.41M
USD
Completed OTHER RESEARCH-RELATED
Single cell quantification of genomic instability in cancer as a determinant of therapeutic response
NATIONAL CANCER INSTITUTE Sloan-Kettering Inst Can Research United States 2021 – 2023

PROJECT ABSTRACT Tumor genetic heterogeneity is an extensive feature of cancer biology and underlies patient response to therapy.One aspect of tumor heterogeneity that has been dif...

$998K
USD